An Ning, Bian Kangqi, Li Chunrui
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, Hubei, China.
Nanjing Bioheng Biotech Co., Ltd., Nanjing, China.
Ann Hematol. 2025 Apr 11. doi: 10.1007/s00277-025-06344-8.
Alemtuzumab is a humanized recombinant monoclonal antibody that specifically targets the CD52 antigen, which is expressed on both malignant and normal T and B lymphocytes. By binding to CD52, alemtuzumab exerts potent antitumor and immunosuppressive effects. Initially approved by the FDA in 2001 for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), alemtuzumab's therapeutic applications have expanded to various hematologic malignancies, including lymphoma, acute leukemia, myelodysplastic syndromes (MDS), aplastic anemia (AA), graft-versus-host disease (GVHD), and chimeric antigen receptor T-cell (CAR-T) therapy. This review evaluates the efficacy and safety of alemtuzumab in these conditions, aiming to synthesize current evidence and provide guidance for clinical practice to optimize the use of alemtuzumab in the treatment of these diseases.
阿仑单抗是一种人源化重组单克隆抗体，它特异性靶向CD52抗原，该抗原在恶性和正常的T淋巴细胞及B淋巴细胞上均有表达。通过与CD52结合，阿仑单抗发挥强大的抗肿瘤和免疫抑制作用。阿仑单抗最初于2001年被美国食品药品监督管理局（FDA）批准用于治疗B细胞慢性淋巴细胞白血病（B-CLL），其治疗应用已扩展到各种血液系统恶性肿瘤，包括淋巴瘤、急性白血病、骨髓增生异常综合征（MDS）、再生障碍性贫血（AA）、移植物抗宿主病（GVHD）以及嵌合抗原受体T细胞（CAR-T）疗法。本综述评估了阿仑单抗在这些病症中的疗效和安全性，旨在综合当前证据并为临床实践提供指导，以优化阿仑单抗在这些疾病治疗中的应用。
